Other TitlesEbola Vaccine Called One Hundred Percent Effective
DescriptionNews release announcing the successful results of an experimental Ebola vaccine in a 2015 trial in Guinea, West Africa. Investigators from the UMB School of Medicine’s Center for Vaccine Development (CVD) and its field site in Mali participated in training field workers in the principles of Good Clinical Practice. The rVSV-ZEBOV vaccine manufactured by Merck, Sharpe & Dohme, was administered to 5,837 people in the project that was led by the World Health Organization (WHO). The results of the trial were published in the journal, Lancet (Vol. 389, no. 10068, Feb. 4, 2017).
University of Maryland, Baltimore. Center for Vaccine Development (CVD)
Merck Sharp & Dohme
Hemorrhagic Fever, Ebola--prevention & control
Ebola Vaccines--therapeutic use